Safety Monitoring of JYNNEOS Vaccine During the 2022 Mpox Outbreak — United States, May 22–October 21, 2022

Duffy, Jonathan; Marquez, Paige; Moro, Pedro L.; Weintraub, Eric; Yu, Yon; Boersma, Peter; Donahue, James G.; Glanz, Jason M.; Goddard, Kristin; Hambidge, Simon J.; Lewin, Bruno; Lewis, Ned; Rouse, Doris J.; Shimabukuro, Tom T.

doi:10.15585/mmwr.mm7149a4

Cited by 38 publications

(34 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, some studies discussed applying the epidemic models, including the fractional models, and other control models 3 – 5 . Other studies discussed the possible vaccinations of the 2022 human MPOX, such as the studies 6 – 9 . Also, some studies discussed some of the indicators of the 2022 human MPOX disease, such as the infection period of the pandemic and other indicators 10 , 11 .…”

Section: Introductionmentioning

confidence: 99%

The study of human monkeypox disease in 2022 using the epidemic models: herd immunity and the basic reproduction number case

Al‐Raeei

2023

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

As of May 2022, a new outbreak of the human monkeypox (MPOX) disease appeared in multiple countries, where the 2022 human MPOX disease spread to more than 109 cases, excluding the suspected cases up to the end of 2022. The deaths of the 2022 human MPOX exceeded 200 cases up to the same date. The human MPOX is not a new disease, this disease was once endemic in some countries on the African continent. Despite this, this disease began to spread in a number of countries around the world in 2022. The first case of the 2022 human MPOX was recorded in the United Kingdom in May. After that date, this disease began to become a pandemic in a number of other countries, such as the United States, Spain, and Brazil. The 2022 human MPOX is a type of viral disease caused by a viral virus, the MPOX virus, and this virus causes rashes and lesions over the skin of the patient, as well as in the mouth of the patient. Multiple effective indicators are employed for the study of the 2022 of the human MPOX, such as the herd immunity of the human MPOX (HIhMPOX), the basic reproduction number of the human MPOX (BRNhMPOX), and the infection period of the human MPOX. This study focuses on the study of the herd immunity of, and the basic reproduction number of the 2022 outbreak of human MPOX in multiple countries around the world. This study employed the semianalytical method of the Susceptible compartment S, Infectious compartment I, Recovered compartment R (SIR) pandemic model including the mortality for the study of the herd immunity, and the basic reproduction number of the 2022 human MPOX disease. It is found that the average value of the herd immunity for the human MPOX disease in 2022 equals to 0.2194, that is, 21.94% for multiple countries, and equals to 35.52% for the United States, and 30.99% for Spain. Also, it is found that the average value of the basic reproduction number of the 2022 human MPOX disease equals to 1.2810 for multiple countries. It is concluded from these values that 21.94% of the total susceptible population has to be immunized in an effective way to prevent the spreading of the disease. Also, based on the previous values, it is concluded that the status of the 2022 MPOX disease is spreading as a pandemic.

show abstract

Section: Introductionmentioning

confidence: 99%

The study of human monkeypox disease in 2022 using the epidemic models: herd immunity and the basic reproduction number case

Al‐Raeei

2023

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

show abstract

“…Also, the CDC considers MVA-BN a safe vaccine, as it only generates mild adverse effects such as pain, redness, and itching in the inoculation site. Severe allergic reactions are extremely rare [35]. Several authors have theorized that the high acceptance of mpox vaccine may be due to the fact the population witnessed a worldwide decline in mortality during the COVID-19 pandemic following the implementation of COVID-19 vaccines [36,37].…”

Section: Discussionmentioning

confidence: 99%

Perceptions and Intention to get vaccinated against Mpox among the LGTBIQ+ Community during the 2022 outbreak: A Cross-Sectional Study in Peru

Araoz-Salinas

Ortiz-Saavedra

Ponce-Rosas

et al. 2023

Preprint

View full text Add to dashboard Cite

Introduction: Vaccination against mpox can control the outbreak by targeting high-risk groups, such as the LGTBIQ + community. The aim of the study was to evaluate the perception and intention to get vaccinated against mpox among the LGTBIQ + community in Peru.Methods We conducted a cross-sectional study from November 1, 2022, to January 17, 2023, in Peru. We included individuals over 18 years old, belonging to the LGBTIQ + community, and residing in the departments of Lima and Callao. To evaluate the factors associated with the intention to be vaccinated, we used Poisson regression with robust variance to create a multivariate model.Results The study comprised 373 individuals who self-identified as members of the LGBTIQ + community. The participants had a mean age of 31 years (SD ± 9), with 85.0% of males, and 75.3% reporting to be homosexual men. The majority (88.5%) expressed their intention to receive the vaccine against mpox. Believing that the vaccine is safe was associated with a higher intention to be vaccinated (aPR: 1.24; 95% CI: 1.02 to 1.50; p = 0.028).Conclusions Our study population showed a high level of mpox vaccination intent. Educational campaigns reinforcing the concept of vaccine safety should be conducted to increase the intention and possibly the vaccination rate in the LGTBIQ + community.

show abstract

“…The opportunity to provide extensive education before vaccination, the workers' baseline knowledge level about working safely with biological hazards, and the controlled and convenient vaccination setting may have contributed to the notable lack of immediate adverse events such as dizziness and fainting, which were seen at higher frequencies in other JYNNEOS vaccination events. 14 Implementation of the alternative regimen using intradermal injection required additional nurse training and introduced new logistic constraints. While intradermal vaccine was intended to extend the limited supply by converting a single-dose vial into a multidose vial, this required significant scheduling coordination to maximize doses from each vial while meeting the needs of workers on all shifts and in different physical locations.…”

Section: Discussionmentioning

confidence: 99%

“…Mild, local adverse effects such as erythema and swelling were common, but the few systemic adverse events reported were also mild and self-limited. The opportunity to provide extensive education before vaccination, the workers’ baseline knowledge level about working safely with biological hazards, and the controlled and convenient vaccination setting may have contributed to the notable lack of immediate adverse events such as dizziness and fainting, which were seen at higher frequencies in other JYNNEOS vaccination events 14 …”

Section: Discussionmentioning

confidence: 99%

Early Experience With an Occupational JYNNEOS (Orthopoxvirus) Vaccination Program

Swift

McDermott

Hainy

et al. 2023

J Occup Environ Med

View full text Add to dashboard Cite

The aim of the study is to identify lessons learned implementing JYNNEOS vaccination for laboratory workers exposed to orthopoxviruses such as mpox. Methods: Workers at risk of laboratory exposure were offered vaccine in a carefully planned occupational health program. Vaccine was procured from the Centers for Disease Control and Prevention (CDC) Drug Service, which has special requirements. Reasons for accepting or declining vaccine and adverse effects were obtained by survey. Results: Most workers accepted JYNNEOS, and occupational risk was the most commonly cited reason for acceptance. Most experienced mild local adverse effects. The administrative requirements of the Centers for Disease Control and Prevention Drug Service are documented. Conclusions: Occupational health programs caring for laboratory workers handling unusual biological agents require careful planning and coordination to facilitate access to vaccines that are not commercially available, anticipate and mitigate barriers to vaccination, and comply with special Centers for Disease Control and Prevention requirements.

show abstract

Safety Monitoring of JYNNEOS Vaccine During the 2022 Mpox Outbreak — United States, May 22–October 21, 2022

Cited by 38 publications

References 6 publications

The study of human monkeypox disease in 2022 using the epidemic models: herd immunity and the basic reproduction number case

The study of human monkeypox disease in 2022 using the epidemic models: herd immunity and the basic reproduction number case

Perceptions and Intention to get vaccinated against Mpox among the LGTBIQ+ Community during the 2022 outbreak: A Cross-Sectional Study in Peru

Early Experience With an Occupational JYNNEOS (Orthopoxvirus) Vaccination Program

Contact Info

Product

Resources

About